title: Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.
authors.affiliation: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.affiliation: Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sunami
authors.affiliation: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Ohashi
authors.affiliation: Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Iida
authors.affiliation: Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.affiliation: Integrative Center of Internal Medicine, Division of Hematology, Gunma University Hospital, Gunma, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Handa
authors.affiliation: Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Matsue
authors.affiliation: Bristol-Myers Squibb K.K, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Miyoshi
authors.affiliation: Oncology Clinical Development, Bristol-Myers Squibb, Princeton, NJ, USA.
authors.forename: E
authors.initials: E
authors.lastname: Bleickardt
authors.affiliation: Department of Hematology, National Hospital Organisation, Shibukawa Medical Center, Shibukawa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Matsumoto
authors.affiliation: Department of Hematology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Taniwaki
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D044466:Asian People; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007564:Japan; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality*; D015996:Survival Rate
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C546027:elotuzumab